Alkem Laboratories Limited
ALKEM · Pharma · NSE
₹5,300
Current Market Price
Fair Value (DCF)
₹5,174
Discount to FV
-2.4%
Updated just now
YieldIQ Score
52/100
Piotroski F-Score
5/9
Economic Moat
Moderate
Confidence
78%
ROE
16.7%
Debt/Equity
0.15
WACC
9.8%
Market Cap
₹63,363 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
21.5%
Return on capital employed
EV / EBITDA
19.1×
Enterprise multiple
Debt / EBITDA
0.6×
Leverage vs earnings
Interest Coverage
18.9×
EBIT covers interest
Current Ratio
2.55×
Short-term liquidity
Asset Turnover
—
Revenue per ₹ of assets
Revenue CAGR (3Y)
8.8%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹5,299.5
Bear case
Discount -71.6%
Base case
Discount -2.4%
Bull case
Discount +25.1%
Ratio Trends
ALKEM · last 9 annual periods
ROE
16.7%
ROCE
21.5%
Operating Margin
—
Debt / Equity
0.15×
PE
27.5×
EV / EBITDA
19.1×
Historical Financials
ALKEM · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹10.5K Cr | ₹11.4K Cr | ₹12.4K Cr | ₹13.0K Cr | ₹14.7K Cr | +8.8% |
| EBITDA | ₹2189 Cr | ₹1709 Cr | ₹2418 Cr | ₹3006 Cr | ₹3414 Cr | +11.7% |
| EBIT | ₹1897 Cr | ₹1412 Cr | ₹2136 Cr | — | — | +3.0% |
| PAT | ₹1646 Cr | ₹984 Cr | ₹1796 Cr | ₹2165 Cr | ₹2302 Cr | +8.8% |
| EPS (diluted) | ₹137.63 | ₹82.31 | ₹150.19 | — | — | +2.2% |
| CFO | ₹1111 Cr | ₹1683 Cr | ₹1948 Cr | ₹1913 Cr | ₹1963 Cr | +15.3% |
| CapEx | ₹-339 Cr | ₹-233 Cr | ₹-259 Cr | ₹-676 Cr | ₹-617 Cr | — |
| FCF | ₹772 Cr | ₹1450 Cr | ₹1689 Cr | ₹1237 Cr | ₹1346 Cr | +14.9% |
| Total Assets | ₹14.1K Cr | ₹13.8K Cr | ₹15.6K Cr | ₹17.7K Cr | ₹20.9K Cr | +10.4% |
| Total Debt | ₹2668 Cr | ₹1397 Cr | ₹1418 Cr | ₹1381 Cr | ₹2047 Cr | -6.4% |
| Shareholders' Equity | ₹8638 Cr | ₹9045 Cr | ₹10.3K Cr | ₹12.0K Cr | ₹13.8K Cr | +12.5% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
ALKEM vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 GLENMARK GLENMARK | — | — | Pending | 11.8% | — |
 BIOCON BIOCON | — | — | Pending | 1.1% | 151.6× |
 LAURUSLABS LAURUSLABS | — | — | Pending | 8.0% | — |
 ABBOTINDIA ABBOTINDIA | — | — | Pending | 32.5% | 35.5× |
 AUROPHARMA AUROPHARMA | — | — | Pending | 9.2% | 21.4× |
Click a ticker to view its fair-value analysis.
Dividend History
19 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹217.00/sh
Last payout
2026-02-20
₹43.00
Peak payout
₹43.00
Trailing yield
0.96%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Alkem Laboratories Limited (ALKEM.NS) trades at 5299.50 vs a model fair value of 5173.97, a gap of -2.4%. Piotroski F-score: 5/9. Moat la...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of ALKEM →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for ALKEM →
Compare
Head-to-head with peers
Compare ALKEM side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse ALKEMNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.